Researchers develop $1 cancer treatment using engineered bacteria

FHS
November 28, 2023
4:50 am

What if a single one-dollar dose could cure cancer?

A Q&A with the global head of Boehringer Ingelheim’s innovation unit

LONDON — At an event here last week, the German pharmaceutical firm Boehringer Ingelheim outlined the projects in its pipeline. There was obesity and liver

October 9, 2023

Risk adjusted net present value: What is the current valuation of Johnson & Johnson’s Nipocalimab?

Nipocalimab is a monoclonal antibody commercialized by Johnson & Johnson, with a leading Phase III program in Acquired (Autoimmune) Hemolytic Anemia.

March 14, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.

Researchers develop $1 cancer treatment using engineered bacteria

A Q&A with the global head of Boehringer Ingelheim’s innovation unit

Risk adjusted net present value: What is the current valuation of Johnson & Johnson’s Nipocalimab?

Experts call for regular screening to prevent complications in people with peripheral arterial disease

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

Subscribe